ANX007 for Age-Related Macular Degeneration

Phase-Based Progress Estimates
Site 30, Albuquerque, NMAge-Related Macular DegenerationANX007 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new drug to see if it can stop or slow the growth of vision loss from GA due to AMD. It will last about 19 months.

Eligible Conditions
  • Age-Related Macular Degeneration (AMD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Baseline to Month 18

Baseline to Month 12
GA lesion growth rate
Baseline to Month 18
Best corrected visual acuity (BCVA)
Low-luminance BCVA (LL-BCVA)
Low-luminance visual acuity deficit (LL-VD)
Safety: Participants with treatment-emergent adverse events (TEAEs)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

Trial Design

4 Treatment Groups

ANX007 Group 1
1 of 4
ANX007 Group 2
1 of 4
Sham Group 3
1 of 4
Sham Group 4
1 of 4

Experimental Treatment

Non-Treatment Group

270 Total Participants · 4 Treatment Groups

Primary Treatment: ANX007 · Has Placebo Group · Phase 2

ANX007 Group 1
Experimental Group · 1 Intervention: ANX007 · Intervention Types: Drug
ANX007 Group 2
Experimental Group · 1 Intervention: ANX007 · Intervention Types: Drug
Sham Group 3
ShamComparator Group · 1 Intervention: Sham comparator · Intervention Types: Other
Sham Group 4
ShamComparator Group · 1 Intervention: Sham comparator · Intervention Types: Other
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to month 18

Who is running the clinical trial?

Annexon, Inc.Lead Sponsor
12 Previous Clinical Trials
528 Total Patients Enrolled
Clinical TrialsStudy DirectorAnnexon, Inc.
2,154 Previous Clinical Trials
876,454 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
How old are they?
18 - 6533.3%
What site did they apply to?
Site 625.0%
Site 425.0%
Site 1125.0%
What portion of applicants met pre-screening criteria?
Met criteria71.4%
Did not meet criteria28.6%
Why did patients apply to this trial?
  • "I am anxious to preserve the vision I have left."
  • "I am trying everything possible to halt the progression of my condition if not improve it. On the first page there was a Jacksonville. FL location but it did not appear on the list of potions to select."
How many prior treatments have patients received?
What questions have other patients asked about this trial?
  • "When would it start?"

Frequently Asked Questions

Does ANX007 present any safety risks to individuals?

"Our team has assigned ANX007 a safety rating of 2, given that there is some substantiating evidence to suggest its protection but no studies yet confirming it's usefulness." - Anonymous Online Contributor

Unverified Answer

Has recruitment begun for this experimental research initiative?

" states that this trial, initially posted on February 26th 2021 and last updated July 1st 2022, is not actively searching for participants. However, there are 189 other promising studies currently recruiting volunteers." - Anonymous Online Contributor

Unverified Answer

What is the scale of this clinical trial across medical facilities?

"Apart from the three previously mentioned sites, participants for this trial can be found in Site 35 Katy, Texas; Site 34 Burleson, California and Site 23 Pasadena, Florida. Additionally there are 46 other enrolment locations." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.